Causes of drug resistance and novel therapeutic opportunities for the treatment of glioblastoma.
Causes of drug resistance and novel therapeutic opportunities for the treatment of glioblastoma.
复制标题
DOI：
10.1054/drup.1998.0062
复制
发表时间：
1999-02
期刊：
影响因子：
--
通讯作者：
M. Nagane;H. Huang;W. Cavenee
中科院分区：
文献类型：
--
作者：
M. Nagane;H. Huang;W. Cavenee
恶性胶质瘤是人类最致命、最难治疗的肿瘤之一，耐药性是其成功治疗的主要障碍之一。人类癌症的分子生物学和遗传学的最新进展为我们提供了对化疗的细胞和分子反应以及耐药性可能发生的详细了解。一些癌基因和肿瘤抑制基因已被证明具有对肿瘤细胞的耐药性，因此应该为癌症治疗提供新的和明确的靶点。除了克服细胞耐药性外，由于血脑屏障这一相对独特的问题，还需要做出特别努力，增加对神经胶质瘤的药物输送。针对这些目标的治疗可能会从综合治疗中受益，包括手术、传统化疗和有针对性地干扰其他生理过程，如血管生成。版权所有1999哈考特出版有限公司。
Malignant gliomas are among the most lethal and intractable of human tumors and drug resistance is one of the major obstacles to their successful treatment. Recent advances in the molecular biology and genetics of human cancers provide a detailed understanding of cellular and molecular responses to chemotherapy and how drug resistance may develop. Several oncogenes and tumor suppressor genes have been shown to confer resistance to tumor cells and should, therefore, provide novel and defined targets for cancer treatment. In addition to overcoming cellular resistance, special efforts to increase drug delivery to glial tumors need to be pursued because of the relatively unique problem of the blood-brain barrier. Treatments aimed at these targets will likely benefit from combined therapies including surgery, traditional chemotherapy and targeted disruption of other physiological processes such as angiogenesis. Copyright 1999 Harcourt Publishers Ltd.